1. Advancing Care Across the Spectrum of Pancreatic Cancer

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Pancreatic Cancer

5. Current Treatment for Pancreatic Cancer Is Insufficient

6. First-Line Treatment of Metastatic Pancreatic Cancer

7. First-Line Gemcitabine

8. FOLFIRINOX for First-Line Treatment

9. Phase 3 IMPACT Trial Gemcitabine + nab-Paclitaxel

10. Selection of First-Line Treatment According to Clinical Features

11. Second-Line Treatment of Metastatic Pancreatic Cancer

12. Phase 3 NAPOLI-1 Trial Study Design

13. NAPOLI-1 Trial Results

14. Treatment Sequencing in Pancreatic Cancer

15. Role of Oxaliplatin in Second-Line Treatment

16. Emerging Therapies for Advanced Pancreatic Cancer

17. Immunotherapy

18. PARP Inhibitors

19. Veliparib in Pancreatic Cancer

20. Molecular Testing in Pancreatic Cancer

21. Advances in Early-Stage Pancreatic Cancer

22. Phase 3 PRODIGE 24/CCTG PA.6

23. PRODIGE 24/CCTG PA.6 Key Results

24. LAPACT Trial

25. LAPACT Trial Results

26. PREOPANC Study Design

27. PREOPANC Key Results

28. Take-Home Messages

29. Abbreviations

30. Abbreviations (cont)

31. Abbreviations (cont)